Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Pneumothorax Following Endoscopic Valve Therapy in Patients With Severe Emphysema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* FEV1 \< 50%, RV\>150%, TLC\>100%~* emphysema confirmed by computed tomography~* pO2 \>60 mmHg (with supplemental oxygen), pCO2 \< 55 mmHg (room condition)~* no significant collateral ventilation (assessed by fissure analysis and/or catheter-based measurement)~* no COPD exacerbation within the past 8 weeks~* daily use of \< 20 mg Prednisolon~* non-smoking for a minimum of 4 months prior to consent~* Patient has provided written informed consent~Exclusion Criteria:~* BMI \< 18 kg/m²~* clinically relevant bronchiectasis~* failed cardiac clearance: defined as myocardial infarction within last 6 weeks, decompensation of heart failure~* Prior lung resection (e.g. lobectomy)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Modified medical care (Type: ACTIVE_COMPARATOR): Patients will undergo 48-hours bed rest after endoscopic valve implantation.
- Standard medical care (Type: NO_INTERVENTION): Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).